CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Brand Name||Adcetris (Resubmission)|
|Generic Name||Brentuximab Vedotin|
|Funding Request||For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates|
|Pre Noc Submission||No|
|NOC Date||February 1, 2013|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||August 27, 2018|
|Submission Deemed Complete||September 11, 2018|
|Prioritization Requested||Requested and Granted|
|Stakeholder Input Deadline ‡||September 11, 2018|
|Check-point meeting||October 23, 2018|
|pERC Meeting||December 13, 2018|
|Initial Recommendation Issued||January 4, 2019|
|Feedback Deadline ‡||January 18, 2019|
|pERC Reconsideration Meeting||February 21, 2019|
|Final Recommendation Issued||March 7, 2019|
|Notification to Implement Issued||March 22, 2019|
|Therapeutic Area||Hodgkin lymphoma (HL)|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.